International Journal of Cancer最新文献

{"title":"Screening outcomes at second FIT screening in individuals with a first time negative FIT-result or low-risk adenomas: Results from a nationwide FIT screening program.","authors":"Pernille Thordal Larsen, Susanne Fogh Jørgensen, Morten Rasmussen, Berit Andersen, Sisse Helle Njor","doi":"10.1002/ijc.35419","DOIUrl":"https://doi.org/10.1002/ijc.35419","url":null,"abstract":"<p><p>In Denmark, participants in faecal immunochemical test (FIT) screening with low-risk adenomas are recommended a return to biennial FIT-screening. However, they participate less than the FIT-negative group (FIT₁-negative) at subsequent screening. Further, it is not clear how much this group benefits from the subsequent screening. We aimed at comparing the CRC incidence before and at the next screening (FIT₂) in the low-risk group to that of those having a FIT-negative result at first time FIT-screening. In this register-based cohort study, we estimated the incidence of interval CRC (ICRC) and results of FIT₂, including the FIT₂-positivity rate and rate of screen detected CRC (SDCRC). Relative risk (RR) comparing the low-risk group to FIT₁-negatives was estimated. Adjustment for age and sex was performed with binary regression and presented with a 95% confidence interval (CI). Incidence of ICRC was 0.17% and 0.08% in the Low-risk group and FIT₁-negative group, respectively, RR 2.18 (95%CI 1.51; 3.16). After adjustment, RR was 1.76 (95%CI: 1.22; 2.55). The FIT₂-positivity rate was 14.4% and 4.4% for the Low-risk group and FIT₁-negative group, respectively. At FIT₂-screening, the detection of SDCRC was 0.36% and 0.16% in the low-risk and FIT₁-negative group, respectively, RR 2.27 (95%CI: 1.46; 3.54), adjusted 1.83 (95% CI: 1.17; 2.85). Despite a recent colonoscopy, participants having low-risk adenomas detected at first colonoscopy in FIT-screening remain at a higher short-term risk of ICRC and SDCRC compared to the FIT₁-negatives. Continuous participation in FIT-screening is important for the Low-risk group.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study.","authors":"Runbo Zhong, Tianqing Chu, Liwen Xiong, Chunlei Shi, Wei Zhang, Xueyan Zhang, Xiaohua Yang, Yuqing Lian, Mengqi Zhang, Hua Zhong, Baohui Han","doi":"10.1002/ijc.35422","DOIUrl":"https://doi.org/10.1002/ijc.35422","url":null,"abstract":"<p><p>Advanced non-small cell lung cancer (NSCLC) with positive PD-L1 expression requires more effective therapeutic options. This study aims to evaluate the efficacy and safety of autologous cytokine-induced killer (CIK) cell therapy combined with the anti-PD-1 antibody toripalimab, with or without chemotherapy, as a first-line treatment for advanced NSCLC. This phase II trial enrolled 40 patients with PD-L1-positive, driver mutation-negative advanced NSCLC between July 2020 and December 2022. Patients were randomly assigned to Arm A (toripalimab + CIK cells + chemotherapy) or Arm B (toripalimab + CIK cells). Progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and safety profiles were evaluated. Subgroup analyses were conducted based on the number of CIK cell cycles received. Arm A showed a significantly longer median PFS compared to Arm B (20.0 vs. 6.0 months, p = 0.0038), while median OS was not reached in Arm A versus 17.0 months in Arm B (p = 0.0479). ORR was 47.4% in Arm A and 60.0% in Arm B. Patients receiving four or more cycles of CIK cells had significantly improved PFS and OS. No new safety concerns were identified. The combination of CIK cells and toripalimab, with or without chemotherapy, demonstrates promising efficacy and safety in patients with advanced PD-L1-positive NSCLC. The addition of chemotherapy may further enhance therapeutic outcomes, making it a potentially superior strategy compared to CIK cells combined with the anti-PD-1 antibody alone.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of extrachromosomal circular DNA associated with genomic repeat sequences in breast cancer.","authors":"Wenxiang Lu, Lingsong Yao, Ying Wang, Fuyu Li, Bingbo Zhou, Wenlong Ming, Yali Jiang, Xiaoan Liu, Yun Liu, Xiao Sun, Yan Wang, Yunfei Bai","doi":"10.1002/ijc.35423","DOIUrl":"https://doi.org/10.1002/ijc.35423","url":null,"abstract":"<p><p>Extrachromosomal circular DNA (eccDNA) has emerged as a potential biomarker for disease due to its stable closed circular structure. However, the diagnostic utility of eccDNA remains underexplored. In this study, we demonstrate that the characteristics of eccDNA associated with genomic repetitive elements change in breast cancer patient tissues and plasma. These changes can serve as signatures for accurate cancer classification. We profiled eccDNA annotated to repeat elements across the genome in tissues and plasma, aggregating each repeat element to the superfamily and subfamily level. Our findings indicate that eccDNA associated with repetitive elements in cancer exhibits regular patterns of enrichment or depletion in specific elements, particularly at the family level. Additionally, these repeat element changes are present in different subtypes of breast cancer, correlated with varying hormone receptor expression. Although there are differences in the landscapes of eccDNA on repetitive elements between cancer tissues and paired plasma, the unique characteristics of eccDNA associated with repetitive sequences in the plasma of cancer patients facilitate better differentiation from normal individuals. These analyses reveal that changes in eccDNA associated with repeat sequences in human cancers can be used as diagnostic biomarkers for cancer patients.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognosis prediction in non-Hodgkin lymphoma by assessing lymphoid organs uptake patterns using baseline ¹⁸F-FDG PET/CT.","authors":"Jie Ding, Xinwei Cheng, Haiyan Wang, Yu Sun, Yihong Yang, Na Qi, Yan Jiang, Xing Chen, Qingyuan Meng, Zhiwen You, Jianjuan Jiang, Jun Zhao","doi":"10.1002/ijc.35412","DOIUrl":"https://doi.org/10.1002/ijc.35412","url":null,"abstract":"<p><p>The prognostic implications of lymphoid organs (LOs) involvement in untreated non-Hodgkin lymphoma (NHL) patients remain underexplored. This study aims to explore the significance of LOs metabolic activity, assessed via ¹⁸F-FDG PET/CT, in predicting the early treatment response and prognosis of NHL patients. A retrospective analysis was conducted on ¹⁸F-FDG PET/CT imaging data of untreated NHL patients from March 2016 to December 2023. Metabolic activity levels of LOs were evaluated and scored. Prognostic parameters included the international prognostic index (IPI), progression-free survival (PFS), overall survival (OS), and the interim efficacy evaluation. The median follow-up time was 15 months. The survival analysis was conducted using Kaplan-Meier and Cox regression methods. We included a total of 125 NHL patients (63 ± 12 years) with baseline ¹⁸F-FDG PET/CT scans. Based on the metabolic scores of LOs, patients were divided into three groups: 36 (28.8%) in the low metabolism group, 64 (51.2%) in the intermediate metabolism group, and 25 (20.0%) in the high metabolism group. LOs metabolic scores emerged as an independent prognostic factor. Patients with high metabolic activity in LOs had significantly shorter PFS and OS compared to those with lower activity (OS HR = 4.56; PFS HR = 3.87; p <0.01). The combination of LOs metabolism and extra-LOs tumor burden can further stratify the risk in NHL patients. Metabolic activity in LOs in ¹⁸F-FDG is a vital prognostic indicator and may predict early treatment response in NHL patients. The incorporation of LOs metabolic assessment into clinical practice could enable more accurate prognosis and tailored treatment strategies.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143699264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk.","authors":"Jiangchuan He, Bilal Alashkar Alhamwe, Sergio Sabroso, Alfredo Carrato, Manuel Hidalgo, Xavier Molero, Mar Iglesias, José Perea, Antoni Farré, Adonina Tardón, Enrique Dominguez-Muñoz, Victor Barberà, Luís Muñoz-Bellvís, Matthias Löhr, William Greenhalf, Michael O'Rorke, Thomas Gress, Tatjana Crnogorac-Jurcevic, Auba Gayà, Alberto Langtry, Jörg Kleeff, Rita Lawlor, Francisco X Real, Harald Renz, Núria Malats","doi":"10.1002/ijc.35397","DOIUrl":"https://doi.org/10.1002/ijc.35397","url":null,"abstract":"<p><p>Studies reported that atopic individuals exhibit a 36% reduced risk of developing pancreatic ductal adenocarcinoma (PDAC); however, the underlying molecular mechanisms remain unclear. This study examines the specific role of type-2 immune response in the atopy-PDAC inverse association. To endotype atopic conditions using type-2 immune effectors (i.e., eosinophils and immunoglobulin-E[IgE]) and investigate their protective effect against PDAC risk, IgE levels were measured in 688 PDAC cases and 558 controls from the PanGenEU case-control study. 'IgE-sensitization' was defined as having >100 kU/L total IgE with lab-tested sensitization to ≥1 food- or aeroallergens. Atopic conditions were determined using the European Community Respiratory Health Survey questionnaire. The UK Biobank cohort's 544 PDAC cases and 92,038 nested controls were categorized based on a threshold of 0.15 × 10⁹ eosinophil cells/L plus self-reported atopy. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using multivariable logistic regression. Restricted cubic splines were applied to examine the nonlinear relationship between type-2 immune effectors and PDAC risk. PDAC risk was not linearly associated with type-2 immune effectors levels. Compared to low IgE-sensitized non-atopic individuals, the low IgE-sensitized atopic population had significantly reduced PDAC risk (OR = 0.56, 95% CI: 0.35-0.84). Similar trends were observed among atopic individuals with low eosinophil counts (OR = 0.67, 95% CI: 0.47-0.95). Atopic conditions were inversely associated with PDAC risk, particularly among those with low levels of type-2 immune effectors. This indicates the protective effect of atopy against PDAC risk is modulated by low type-2 immune response.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alcohol and smoking habits in association with hepatocellular carcinoma risk.","authors":"Elom K Aglago, Ines Ramos, Pekka Keski-Rahkonen, Chrysovalantou Chatziioannou, Heinz Freisling, Veronika Fedirko, Marc J Gunter, Christina C Dahm, Fie Langmann, Nicola Bondonno, Anne Tjønneland, Gianluca Severi, Therese Truong, Verena Katzke, Rudolf Kaaks, Manuela Bergmann, Matthias B Schulze, Giovanna Masala, Valeria Pala, Maria Santucci de Magistris, Chiara Di Girolamo, Marko Lukic, Inger Torhild Gram, Catalina Bonet, Maria-Jose Sánchez, María-Dolores Chirlaque, Pilar Amiano, Marcela Guevara, Roel Vermeulen, Jonas Manjer, Linda Eriksson, Tim J Key, Ana-Lucia Mayen, Laure Dossus, Elisabete Weiderpass, Alicia K Heath, Pietro Ferrari, Mazda Jenab","doi":"10.1002/ijc.35401","DOIUrl":"https://doi.org/10.1002/ijc.35401","url":null,"abstract":"<p><p>We assessed hepatocellular carcinoma (HCC) risk associated with smoking and alcohol consumption and their interactions, using both questionnaire data and objective serum biomarkers. Information on smoking and alcohol consumption was collected at baseline from 450,112 participants of the EPIC cohort, among whom 255 developed HCC after a median follow-up of 14 years. In a nested case-control subset of 108 HCC cases and 108 matched controls, known biomarkers of smoking (cotinine, nicotine) and habitual alcohol consumption (2-hydroxy-3-methylbutyric acid) were annotated from untargeted metabolomics features. Multivariable-adjusted hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were computed, and multiplicative and additive interaction parameters were calculated. Compared to never smokers, current smokers had a higher HCC risk (HR = 2.46, 95% CI = 1.77-3.43) dose-dependently with the number of cigarettes smoked per day (P_trend <.001). Compared to light drinkers, HCC risk was higher in former (HR = 3.20, 95% CI = 1.70-6.03), periodically heavy (HR = 1.98, 95% CI = 1.11-3.54), and always heavy (HR = 5.51, 95% CI = 2.39-12.7) drinkers. Higher HCC risk was also observed in the highest versus the lowest tertiles of cotinine (OR = 4.88, 95% CI = 1.52-15.70), nicotine (OR = 5.80, 95% CI = 1.33-25.30) and 2-hydroxy-3-methylbutyric acid (OR = 5.89, 95% CI = 1.33-26.12). Questionnaire-assessed smoking and alcohol exposures did not demonstrate an HCC risk interaction at the multiplicative (MI = 0.88, 95% CI = 0.40-1.96) or additive (RERI = 0.71, 95% CI = -10.1 to 23.6; attributable proportion = 0.17, 95% CI = -0.52 to 1.16; synergy index = 1.27, 95% CI = 0.98-1.66) scales. Similar analyses with cotinine, nicotine, and 2-hydroxy-3-methylbutyric acid also did not show interactions between smoking and alcohol consumption on HCC risk. Smoking and alcohol consumption are strong independent risk factors for HCC and do not appear to synergistically impact its risk, but larger studies are needed.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.","authors":"Mathieu Virazels, Amélie Lusque, Stéphanie Brayer, Matthieu Genais, Carine Dufau, Jean Milhès, Thomas Filleron, Cécile Pagès, Vincent Sibaud, Laurent Mortier, Olivier Dereure, Maha Ayyoub, Amandine Fabre, Nathalie Andrieu-Abadie, Vera Pancaldi, Céline Colacios, Nicolas Meyer, Bruno Ségui, Anne Montfort","doi":"10.1002/ijc.35416","DOIUrl":"https://doi.org/10.1002/ijc.35416","url":null,"abstract":"<p><p>Resistance to immune checkpoint inhibitors (ICI) in cancer patients is not fully understood, and predictive biomarkers are lacking. MELANFα (NCT03348891) is an open-label, prospective, multicenter cohort of 60 patients with advanced melanoma receiving ICI (bitherapy: ipilimumab + nivolumab; monotherapy: pembrolizumab or nivolumab). The primary objective was to evaluate whether changes in plasma TNF between baseline (W0) and week 12 (W12) identified patients with non-progressive disease at W12. Secondary and exploratory objectives were to assess the association between plasma TNF, tumor response, and changes in circulating T cells. Plasma TNF increased along therapy, but its W12/W0 fold change was not associated with non-progressive disease at W12. However, plasma TNF levels at W12 were significantly higher in non-responders than in responders across therapies (p = .0129). The remodeling of circulating T cell subpopulations was mostly triggered by bitherapy. Increased proportions of circulating central memory and effector memory CD8 T cells after bitherapy were positively and negatively associated with response to treatment, respectively. In this cohort, circulating T cells from responders and non-responders also displayed distinct molecular characteristics. Indeed, responders showed an increased proportion of CD8 T cells with low enrichment of TNF-related pathways and high cytotoxic potential, while non-responders displayed increased proportions of circulating CD8 EM T cells enriched for TNF-related pathways and directed toward cytokine expression. In conclusion, our study shows that elevated plasma TNF and enriched TNF pathways in T cells are associated with poorer clinical outcomes, reinforcing the notion that TNF may dampen ICI efficacy.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hematologic and molecular responses to ropeginterferon alfa-2b therapy of polycythemia vera: 48-week results from a prospective study.","authors":"Seug Yun Yoon, Sung-Soo Yoon, Deok-Hwan Yang, Gyeong-Won Lee, Sang Kyun Sohn, Ho-Jin Shin, Sung Hwa Bae, Chul Won Choi, Eun-Ji Choi, June-Won Cheong, Soo-Mee Bang, Joon Seong Park, Suk Joong Oh, Yong Park, Young Hoon Park, Sung-Eun Lee","doi":"10.1002/ijc.35411","DOIUrl":"https://doi.org/10.1002/ijc.35411","url":null,"abstract":"<p><p>To prevent thrombosis in patients with polycythemia vera (PV), achieving a complete hematologic response (CHR) is highly recommended in practice. In addition, a reduced JAK2 V617F mutation burden is expected to have a disease-modifying effect, and its molecular response (MR) is currently of significant interest. This study aimed to assess the association between CHR and MR in patients with PV following treatment with ropeginterferon alfa-2b. This phase 2, single-arm, open-label, investigator-initiated trial was conducted at 16 sites in South Korea. Ninety-nine patients were treated with ropeginterferon alfa-2b subcutaneously every 2 weeks, at doses of 250 μg (week 1), 350 μg (week 3), and 500 μg (week 5), until week 48. CHRs were 27% (25/94), 46% (40/87), 56% (47/84), and 63% (51/81) at 12, 24, 36, and 48 weeks, respectively. The MR rates were 32% (28/88), 36% (29/81), 49% (38/77), and 57% (42/74) at 12, 24, 36, and 48 weeks, respectively. The Phi Coefficient for the association between CHR and MR was 0.6146 (p < .0001) at 48 weeks. In the subgroup analysis, patients with hydroxyurea resistance or intolerance, and those who were hydroxyurea-naïve, had similar results in terms of the CHR. In conclusion, CHR and MR were observed to be associated in patients with PV treated with ropeginterferon.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in incidence and mortality of colorectal cancer in Denmark from 2007 to 2022.","authors":"Ida Ravnsbæk Johannsen, Anders Kindberg Boysen, Frank V Mortensen, Jakob Kirkegård","doi":"10.1002/ijc.35400","DOIUrl":"https://doi.org/10.1002/ijc.35400","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer in the Western world and represents a significant burden on healthcare systems worldwide. We aimed to describe temporal trends in incidence, tumor characteristics, and survival for patients with CRC in a nationwide, population-based cohort in Denmark. We used population-based Danish healthcare registries to study all patients diagnosed with CRC from 2007 to 2022. Exactly 76,955 people in Denmark were diagnosed with CRC from 2007 to 2022. ASIRs were relatively stable from 2007 to 2013, with an ASIR of 65.8 per 100,000 for colon cancer and 32 per 100,000 for rectal cancer. In 2014, an increase in incidence was observed (79.8 per 100,000 for colon cancer and 37.4 per 100,000 for rectal cancer), followed by a decline in later years. Median survival times were 4.1 (IQR: 0.8 to 14.1) years for patients diagnosed between 2007 and 2010, 5.3 (IQR: 1.1 to -) years for patients diagnosed from 2011 to 2013, and 7.6 (IQR: 1.7 to -) years for patients diagnosed from 2014 to 2017. The assessment of mutational and molecular profiles increased consistently throughout the study period. We observed an initial increase in CRC incidence in 2014, corresponding with the implementation of the national screening program, followed by a subsequent decline. In recent years, the incidence has dropped below pre-screening levels. Additionally, the increasing use of molecular and mutational profiling reflects the growing complexity and multidisciplinary nature of CRC management.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial.","authors":"Yuan Gao, Ann-Lii Cheng, Lee X Li, Natalie Parent, Ganessan Kichenadasse, Christos S Karapetis, Andrew Rowland, Ashley M Hopkins, Michael J Sorich","doi":"10.1002/ijc.35407","DOIUrl":"https://doi.org/10.1002/ijc.35407","url":null,"abstract":"<p><p>The use of Immune checkpoint inhibitors (ICIs) as monotherapy for patients with hepatocellular carcinoma (HCC) has been associated with an increased risk of hyperprogressive disease (HPD), the occurrence of which carries a poor prognosis. However, it is unknown whether contemporary frontline treatment with the combination of atezolizumab and bevacizumab causes significant HPD. This study conducted a secondary analysis of patient-level data from the IMbrave150 randomized controlled trial of atezolizumab plus bevacizumab versus sorafenib for frontline treatment of HCC. Multiple established definitions of early progression and treatment failure applicable to clinical trials were evaluated, including Response Evaluation Criteria in Solid Tumours (RECIST) HPD, HPD based on percent change of sum of longest diameter (SLD HPD), treatment failure HPD (TF HPD), and fast progression (FP). The incidence of these measures was compared between arms. The risk factors for and prognosis of TF HPD were evaluated. The risk of RECIST HPD and TF HPD was significantly lower with atezolizumab plus bevacizumab treatment than with sorafenib treatment-odds ratio for RECIST HPD: 0.29 (95% CI 0.01 to 0.82), TF HPD: 0.30 (0.17, 0.54). TF HPD was similarly associated with poor prognosis, irrespective of treatment arm. High blood alpha-fetoprotein and neutrophil-to-lymphocyte ratio were both associated with an increased risk of TF HPD. For all definitions of early progression/treatment failure, the risk was either significantly lower with atezolizumab plus bevacizumab than with sorafenib, or there were no differences. Atezolizumab plus bevacizumab treatment is unlikely to cause significant HPD.</p>","PeriodicalId":180,"journal":{"name":"International Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}